913 / 1631
The paradigm for study design….don’t change practice yet
R-CHOP
R-CHOP+X
DLBCL
R
Biological and
clinical
stratification
Ongoing X=
Lenalidomide
Ibrutinib
Bortezomib
Brentuximab
Everolimus
Tazemetostat
More to come…
Can we practically
deliver this design in
phase III with so many
agents?